J Am Chem Soc. 2021 Jun 23;143(24):8957-8961. doi: 10.1021/jacs.1c02664. Epub 2021 Jun 10.
Isothermal amplification strategies capable of rapid, inexpensive, and accurate nucleic acid detection provide new options for large-scale pathogen detection, disease diagnosis, and genotyping. Here we report a highly sensitive multicomponent XNA-based nucleic acid detection platform that combines analyte preamplification with X10-23-mediated catalysis to detect the viral pathogen responsible for COVID-19. The platform, termed RNA-Encoded Viral Nucleic Acid Analyte Reporter (REVEALR), functions with a detection limit of ≤20 aM (∼10 copies/μL) using conventional fluorescence and paper-based lateral flow readout modalities. With a total assay time of 1 h, REVEALR provides a convenient nucleic acid alternative to equivalent CRISPR-based approaches, which have become popular methods for SARS-CoV-2 detection. The assay shows no cross-reactivity for other in vitro transcribed respiratory viral RNAs and functions with perfect accuracy against COVID-19 patient-derived clinical samples.
等温扩增策略能够快速、廉价、准确地进行核酸检测,为大规模病原体检测、疾病诊断和基因分型提供了新的选择。在这里,我们报告了一种基于 XNA 的高灵敏度多组分核酸检测平台,该平台将分析物预扩增与 X10-23 介导的催化相结合,以检测导致 COVID-19 的病毒病原体。该平台称为 RNA 编码病毒核酸分析物报告器 (REVEALR),使用传统荧光和基于纸的侧流读取模式,检测限低至 ≤20 aM(约 10 拷贝/μL)。REVEALR 的总测定时间为 1 小时,为等效的基于 CRISPR 的方法提供了一种便捷的核酸替代方法,该方法已成为 SARS-CoV-2 检测的流行方法。该测定法对其他体外转录的呼吸道病毒 RNA 无交叉反应性,对 COVID-19 患者来源的临床样本具有完美的准确性。